EUCTR2005-000808-14-SE进行中（未招募）不适用
A randomized, double-blind, parallell-group, controlled study of topical pentane-1,5-diol hydrogel in patients with impetigo
Ambria Dermatology0 个研究点目标入组 88 人开始时间: 2005年2月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Males and females; age 2 years or older
- •-Clinical diagnosis of impetigo
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Severe organic disease or other disease which may interfere with the administration or assessment of study medication such as severe immunodeficiency or tumor bearing disease; current use of drugs/preparations which may interfere with the study evaluation.
- •-Pregnant or lactating women or female patients without an ongoing efficient contraceptive method
研究者
相似试验
招募中
2 期
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin Compared to Each Monotherapy, in Adult Patients With NASH and Liver FibrosisCTRI/2020/08/027184ovartis Healthcare Pvt Ltd
尚未招募
3 期
A clinical trial of herbal products in the management of knee osteoarthritisCTRI/2023/07/054799Phytoveda Pvt. Ltd.
尚未招募
Unknown
Clinical study of nutritional formulations in the management of knee osteoarthritis.CTRI/2024/07/070163ife Synergy
招募中
3 期
Comparing the safety and efficacy of Altelyse with Actilyse in acute myocardial infarctioIRCT20190729044366N1Arena Life Science Company150
进行中（未招募）
1 期
A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmakokinetics of HD201 to Herceptin® in patients with HER2+ early breast canceron-metastatic, unilateral, newly diagnosed, operable early breast cancer (EBC) of clinical stage II and III including inflammatory breast cancer.EUCTR2016-004019-11-PLPrestige BioPharma Pte Ltd500